Amid a highly volatile market, here is an outlier stock that surged 9%

• Shares of Natco Pharma surged 9% today as it launched its first generic variant of Revlimid in the US market.
• Revlimid, also known as lenalidomide, is an oral cancer drug that is used for the treatment of blood cancer.
• While the market conditions remained volatile, Natco Pharma was among the outlier stocks to surge sharply.

The Indian equity market remained on a negative note, on Tuesday morning, amid weakness across most global markets, but the shares of Hyderabad-based Natco Pharma became an outlier by surging 9%.

This comes after the company launched its first generic variant of Revlimid in the US market. Revlimid, also known as lenalidomide, is an oral cancer drug that is used for the treatment of multiple myeloma, which is basically blood cancer.

In a press release, Natco said the drug has been launched in 5 milligram (mg), 10mg, 15mg and 25mg strengths in the US market.

"The above strengths of lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment,” according to the press release.

Lenalidomide was approved for medical use in the US in 2005 and is also on the World Health Organization's List of Essential Medicines.


SEE ALSO: Here are the women who lead India’s billion dollar startups
Women’s Day 2022: These are the top 10 richest Indian women